ADAP

ADAP

Adaptimmune Therapeutics is a clinical-stage biotech focused on developing T-cell therapies for cancer.
It is primarily known as a leader in developing novel SPEAR T-cell therapies targeting solid tumors.

$0.00 +0.00 (+0.00%)

Updated: January 12, 2026, 16:00 EST

Analyzed by Rockflow Bobby Quantitative Model โœ“ Updated Daily

Investment Opinion: Should I buy ADAP Today?

Based on a comprehensive analysis, ADAP presents a highly speculative and risky investment profile that is difficult to recommend for most investors.

The company's fundamentals are deeply concerning, with revenue contracting and operating expenses far outstripping income, leading to significant and persistent losses. While short-term liquidity is adequate, the extremely negative cash flow and poor operational efficiency metrics indicate fundamental business challenges. The stock's high beta of 2.5 signals extreme volatility, amplifying the risk for shareholders.

Given the severe profitability issues, negative valuation ratios, and lack of positive catalysts evident in the data, a cautious approach is warranted. For investors with a very high risk tolerance, any consideration would be a speculative bet on a future turnaround, which is not supported by current operational performance. Therefore, ADAP is not worth buying at this time. Investors should monitor for sustained improvements in revenue growth and a credible path to profitability before reconsidering.

CTA Banner

ADAP 12-Month Price Forecast

RockFlow Model Forecast: Three Scenarios for 2026

Based on the comprehensive analysis, the 12-month outlook for ADAP is decidedly negative. The key catalysts for any potential upside are virtually nonexistent, relying entirely on a hypothetical and unsupported future turnaround. The primary risks are severe and immediate, including unsustainable cash burn, persistent losses, and extreme share price volatility due to its high beta. Given the lack of analyst targets and the profound fundamental challenges, a target price range cannot be established, and the stock is only suitable for the most speculative investors willing to risk a near-total loss.

Wall Street Consensus

Most Wall Street analysts are optimistic about ADAP's 12-month outlook, with consensus target around $0.00, indicating expected upside potential.

Average Target
$0.00
3 analysts
Implied Upside
+0%
vs. current price
Analyst Count
3
covering this stock
Price Range
$0 - $0
Analyst target range
Buy Buy
0 (0%)
Hold Hold
2 (67%)
Sell Sell
1 (33%)

Bulls vs Bears: ADAP Investment Factors

Overall, ADAP has investment potential but also faces challenges. Here are key factors to weigh before investing.

Bullish Bullish
  • Heavy Call Option Buying: Investors purchased 4,105 call options, signaling bullish sentiment.
  • Significant Stock Surges: Shares rose 52% and 42% on separate days due to momentum.
  • Potential Turnaround Speculation: Recent volatility sparks debate about a possible biotech turnaround.
Bearish Bearish
  • Voluntary Nasdaq Delisting: Company plans to delist from Nasdaq, causing a 62.5% stock plunge.
  • Weiss Sell Rating: Weiss Ratings reissued a 'Sell (E+)' rating on the stock.
  • High Investor Uncertainty: Delisting and extreme price swings create significant uncertainty for investors.
Reward Banner

ADAP Technical Analysis

Analysis cannot be completed due to insufficient data. Multiple critical data points are unavailable, including the current price and its recent performance metrics.

Without the 1-month and 3-month percentage changes, it is impossible to assess short-term performance or compare it against the market benchmark. The absence of this data renders a short-term trend analysis inconclusive.

The current price's position relative to its 52-week high and low cannot be determined without the necessary figures. While the beta of 2.492 confirms extreme volatility, the overbought or oversold status is unidentifiable. A complete analysis requires all fundamental data points.

๐Ÿ“Š Beta
2.49
2.49x market volatility
๐Ÿ“‰ Max Drawdown
0.0%
Largest decline past year
๐Ÿ“ˆ 52-Week Range
$0-$0
Price range past year
๐Ÿ’น Annual Return
+0.0%
Cumulative gain past year
Period ADAP Return S&P 500

ADAP Fundamental Analysis

ADAP demonstrates concerning revenue contraction despite improving gross margins (81.7% in Q2), with quarterly revenue declining from $7.3 million to $13.7 million while maintaining substantial losses evidenced by -221.8% net margin. The company's operating expenses significantly outpace revenue generation, resulting in negative operating income ratios exceeding -200%. Overall profitability remains deeply challenged despite some sequential improvement in absolute losses from Q1 to Q2.

The company maintains adequate short-term liquidity with current and quick ratios of 1.52 and 1.29 respectively, though cash ratio of 0.51 indicates limited immediate cash coverage. Debt metrics appear distorted by negative equity, while cash flow remains severely negative with operating cash flow to sales ratio of -254.3%, indicating fundamental cash generation challenges despite the apparently moderate debt ratio of 37.3%.

Operational efficiency metrics reveal significant challenges, with negative returns on assets (-23.2%) and capital employed (-38.3%) reflecting poor asset utilization. The asset turnover of 0.10 indicates inefficient revenue generation relative to the asset base, while the extended cash conversion cycle of 262 days highlights working capital management inefficiencies. These metrics collectively point to substantial operational headwinds requiring improvement.

Quarterly Revenue
$0.0B
2025-03
Revenue YoY Growth
+28.3%
YoY Comparison
Gross Margin
87.9%
Latest Quarter
Free Cash Flow
$-0.1B
Last 12 Months

Revenue & Net Income Trends (2 Years)

Revenue Breakdown

RockFlow Bobby - Your AI Investment Partner

Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions

Try Now & Get Tesla Stock Reward

Valuation Analysis: Is ADAP Overvalued?

Valuation Level: ADAP exhibits negative valuation ratios across most metrics including PE, PB, and EV/EBITDA, indicating the company is currently unprofitable and trading below book value. The positive PS ratio of 4.63 reflects investor valuation based on revenue generation rather than earnings. These negative fundamental metrics suggest the stock's valuation cannot be meaningfully assessed using traditional profitability-based measures.

Peer Comparison: A comprehensive peer analysis cannot be conducted due to the unavailability of industry average data. However, the negative profitability metrics suggest ADAP faces operational challenges relative to profitable industry peers. The PS ratio of 4.63 warrants contextual industry comparison to determine if the market is appropriately pricing ADAP's revenue stream relative to sector norms.

Current PE
-0.1x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range -9ร—-44ร—
vs. Industry Avg
-100.1%
Industry PE ~60.3ร—
EV/EBITDA
-3.3x
Enterprise Value Multiple

Investment Risk Disclosure

Volatility Risk: ADAP exhibits significantly elevated volatility risk, as evidenced by its beta of 2.492, indicating the stock is approximately 2.5 times more volatile than the broader market. This high beta suggests the potential for substantial price swings, though the impact is underscored by the unavailability of a maximum drawdown figure, which would quantify the worst-case historical loss.

Other Risks: The risk assessment is complicated by the lack of available short interest data, which prevents an analysis of bearish sentiment or potential for a short squeeze. Overall, the primary identifiable risk remains its extreme market sensitivity, while other metrics require further data for a complete evaluation.

FAQs

Is ADAP a good stock to buy?

Bearish. Avoid ADAP due to its planned Nasdaq delisting creating extreme uncertainty, deeply negative profitability and cash flow metrics, and a unanimous "Sell" analyst rating. This stock is unsuitable for most investors; only highly speculative traders willing to accept extreme volatility and potential total loss should consider it.

Is ADAP stock overvalued or undervalued?

Based on the provided data, ADAP appears substantially overvalued. The stock exhibits negative profitability ratios (PE and PB are negative) while trading at a PS ratio of 4.63, which indicates investors are paying a significant premium for its sales despite deep operational losses and declining revenue. Key metrics like a negative operating margin exceeding -200% and a PS ratio that likely exceeds profitable peers suggest the current price is not justified by its financial performance or growth prospects, which are severely challenged.

What are the main risks of holding ADAP?

Based on the provided information, here are the key risks of holding ADAP stock, ordered by importance:

1. Severe Profitability and Cash Burn Risk: The company is experiencing deep losses (net margin of -221.8%) and critically negative operating cash flow (-254.3% of sales), indicating a fundamental challenge in sustaining operations without additional funding. 2. Extreme Market Volatility Risk: ADAP's high beta of 2.492 signifies the stock is approximately 2.5 times more volatile than the broader market, exposing investors to the potential for substantial price swings. 3. Operational Inefficiency Risk: Key operational metrics, including a very low asset turnover (0.10) and an extremely long cash conversion cycle (262 days), reveal significant inefficiencies in asset utilization and working capital management. 4. High Fixed-Cost Structure Risk: Despite a high gross margin (81.7%), the companyโ€™s operating expenses vastly outpace its declining revenue, resulting in operating margins worse than -200% and demonstrating a challenging path to profitability.

What is the price forecast for ADAP in 2026?

Based on the provided analysis, a reliable ADAP stock forecast for 2026 cannot be established with any confidence. The key growth drivers are absent, with the outlook dependent entirely on a hypothetical, unsupported corporate turnaround to reverse severe revenue contraction and unsustainable cash burn. The primary assumptions are that the company's profound operational and financial challenges will persist, making any target price purely speculative. This forecast carries extreme uncertainty, and the stock remains suitable only for investors willing to accept a high risk of a near-total loss.